Lipid metabolism and Alzheimer's disease: pathways and possibilities.
BACKGROUND
Alzheimer's disease (AD) is a growing condition in dire need of new therapeutics for its cure. Currently marketed drugs only provide symptomatic relief and do not intervene in disease-modifying pathways. Deposition of amyloid beta peptides in the brain is considered to be at the core of pathological events in AD. Studies indicate that lipid/lipoprotein metabolism has a role in several steps in the etiology of AD.


OBJECTIVE
Here we review the molecular pathways by which lipid metabolism may influence AD and could form the basis for design of new disease modifying therapeutics.


CONCLUSIONS
Modulation of lipid metabolism has excellent potential to provide new avenues for disease modifying drugs for AD.
Saxena
Uday
U
Kareus Therapeutics, 2919 Cravey Trail, Atlanta, GA 30345, USA. usaxena@kareustherapeutics.com
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*
D016229:Amyloid beta-Peptides